ChemicalBook > CAS DataBase List > Darifenacin

Darifenacin

Product Name
Darifenacin
CAS No.
133099-04-4
Chemical Name
Darifenacin
Synonyms
CS-773;UK88525;UK-88525;UK 88525;DARIFENACIN;Darifenacin, >=98%;Darifenacin USP/EP/BP;Tolafentrine Impurity 16;2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-dip;2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphe
CBNumber
CB1506695
Molecular Formula
C28H30N2O2
Formula Weight
426.55
MOL File
133099-04-4.mol
More
Less

Darifenacin Property

alpha 
25D -20.6° (c = 1.0 in methylene chloride)
Boiling point:
614.3±55.0 °C(Predicted)
Density 
1.192±0.06 g/cm3(Predicted)
storage temp. 
2-8°C
solubility 
Soluble in DMSO
form 
Powder
pka
pKa (25°): 9.2
color 
White to off-white
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

ChemScene
Product number
CS-1168
Product name
Darifenacin
Packaging
5mg
Price
$80
Updated
2021/12/16
Matrix Scientific
Product number
093128
Product name
2-(1-(2-(2,3-Dihydrobenzofuran-5-yl)ethyl)-pyrrolidin-3-yl)-2,2-diphenylacetamide
Purity
95+%
Packaging
250mg
Price
$567
Updated
2021/12/16
Biorbyt Ltd
Product number
orb146146
Product name
Darifenacin
Purity
>98%
Packaging
100mg
Price
$578
Updated
2021/12/16
Medical Isotopes, Inc.
Product number
D33903
Product name
Darifenacin-d4
Packaging
1mg
Price
$640
Updated
2021/12/16
AK Scientific
Product number
Q569
Product name
Darifenacin
Packaging
250mg
Price
$815
Updated
2021/12/16
More
Less

Darifenacin Chemical Properties,Usage,Production

Description

Darifenacin is a novel muscarinic M3 selective antagonist for the once-daily oral treatment of urinary incontinence and overactive bladder. The majority of overactive bladder symptoms are thought to result from the overactivity of the detrusor muscle, which is primarily mediated by acetylcholine-induced stimulation of muscarinic M3 receptors in the bladder. Consequently, antimuscarinic agents have become the mainstay of overactive bladder treatment. Darifenacin has a higher level of M3 selectivity than the previously marketed antimuscarinic agents. It has Ki values of 16nM for M1, 50 nM for M2, and 1.6 nM for M3 receptors. It is slightly more M3 selective than solifenacin (M1:Ki=25 nM, M2:Ki=126 nM, M3:Ki=10 nM), which was launched in 2004. Darifenacin is significantly more selective than other muscarinics such as tolterodine, oxybutynin, and trospium, which are all essentially equipotent against M1, M2, and M3 receptors. In addition,darifenacin demonstrates greater effect on tissues in which the predominant receptor type is M3 rather than M1 or M2. In vitro darifenacin inhibits carbacholinduced contractions with greater potency in isolated guinea-pig bladder (M3) than in guinea-pig atria (M2) or dog saphenous vein (M1). In animal models, it shows greater selectivity for inhibition of detrusor contraction over salivation or tachycardia.Darifenacin is supplied as a controlled release formulation, and the recommended dosage is 7.5 mg once, daily. Darifenacin is rapidly and completely absorbed from the GI tract after oral administration, with maximum plasma levels achieved after about 7 h. The elimination half-life is approximately 3 h, but because of the controlled release characteristics of the formulation, the drug is suitable for once-daily dosing. Steady-state plasma levels are achieved within 6 days of commencing treatment. Darifenacin exhibits high-protein binding (98%), a volume of distribution of 163 L, and a clearance of 40 L/h. It has low oral bioavailability (15–19%) due to extensive first-pass metabolism by CYP3A4 and CYP2D6, but this can be saturated after multiple administrations. The major circulating metabolites are produced by monohydroxylation and N-dealkylation; however, none contribute significantly to the overall clinical effect of darifenacin. Approximately 58% of the dose is excreted in urine and 44% in feces; only a small percentage (3%) of the excreted dose is unchanged darifenacin.

Originator

Pfizer (US)

Uses

Treatment for an overactive bladder.

Definition

ChEBI: 2-[(3S)-1-Ethylpyrrolidin-3-yl]-2,2-diphenylacetamide in which one of the hydrogens at the 2-position of the ethyl group is substituted by a 2,3-dihydro-1-benzofuran-5-yl group. It is a selective antagonist for the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions, and is used as the hydrobromide salt in the management of urinary incontinence.

brand name

Enablex (Novartis);Emselex.

Clinical Use

Symptomatic treatment of urinary incontinence,
frequency or urgency

Drug interactions

Potentially hazardous interactions with other drugs
Anti-arrhythmics: increased risk of antimuscarinic side effects with disopyramide
Antifungals: concentration increased by ketoconazole - avoid; avoid with itraconazole.
Antivirals: avoid with fosamprenavir, atazanavir, indinavir, lopinavir, ritonavir, saquinavir and tipranavir.
Calcium-channel blockers: avoid with verapamil
Ciclosporin: avoid concomitant use.

Metabolism

After an oral dose, darifenacin is subject to extensive first-pass metabolism and has a bioavailability of about 15-19%. Darifenacin is metabolised in the liver by the cytochrome P450 isoenzymes CYP2D6 and CYP3A4. Most of a dose is excreted as metabolites in the urine and faeces.

Darifenacin Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Darifenacin Suppliers

Canada 1 China 94 Europe 1 Germany 1 India 14 United States 17 Global 128
LGM Pharma
Tel
1-(800)-881-8210
Fax
615-250-9817
Email
inquiries@lgmpharma.com
Country
United States
ProdList
2123
Advantage
70
BOC Sciences
Tel
1-631-485-4226; 16314854226
Email
info@bocsci.com
Country
United States
ProdList
14055
Advantage
65
MedChemexpress LLC
Tel
021-58955995
Fax
609-228-5909
Email
sales@medchemexpress.cn
Country
United States
ProdList
4861
Advantage
58
AdooQ BioScience, LLC
Tel
+1 (866) 930-6790
Fax
+1 (866) 333-9607
Email
info@adooq.com
Country
United States
ProdList
2782
Advantage
58
Musechem
Tel
+1-800-259-7612
Fax
+1-800-259-7612
Email
info@musechem.com
Country
United States
ProdList
4660
Advantage
60
TargetMol Chemicals Inc.
Tel
+1-781-999-5354 +1-00000000000
Email
marketing@targetmol.com
Country
United States
ProdList
32161
Advantage
58
Cckinase, Inc.
Tel
+1 (732)236-3202
Email
sales@cckinase.com
Country
United States
ProdList
2738
Advantage
58
Alchem Pharmtech,Inc.
Tel
8485655694
Email
sales@alchempharmtech.com
Country
United States
ProdList
63687
Advantage
58
MedChemExpress
Tel
--
Fax
--
Email
sales@medchemexpress.com
Country
United States
ProdList
6398
Advantage
58
Matrix Scientific
Tel
--
Fax
--
Email
sales@matrixscientific.com
Country
United States
ProdList
6632
Advantage
80
CacheSyn Inc.
Tel
--
Fax
--
Email
info@cachesyn.com
Country
United States
ProdList
695
Advantage
50
SynFine Research
Tel
--
Fax
--
Email
research@synfine.com
Country
United States
ProdList
1024
Advantage
68
Focus Synthesis LLC
Tel
--
Fax
--
Email
acd@focussynthesis.com
Country
United States
ProdList
2487
Advantage
61
Waterstone Technology, LLC
Tel
--
Fax
--
Email
sales@waterstonetech.com
Country
United States
ProdList
6786
Advantage
30
ACIC Fine Chemicals Inc.
Tel
--
Fax
--
Email
sales@acic.com
Country
United States
ProdList
492
Advantage
48
AK Scientific, Inc.
Tel
--
Fax
--
Email
sales@aksci.com
Country
United States
ProdList
6347
Advantage
65
Manus Aktteva, India.
Tel
--
Fax
--
Email
manusaktteva@gmail.com
Country
United States
ProdList
67
Advantage
47
More
Less

View Lastest Price from Darifenacin manufacturers

Hebei Mingeng Biotechnology Co., Ltd
Product
Darifenacin 133099-04-4
Price
US $200.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
1000kg/Month
Release date
2022-11-27
Shijiazhuang Gantuo Biotechnology Co., Ltd
Product
Darifenacin 133099-04-4
Price
US $100.00/mg
Min. Order
10mg
Purity
99%
Supply Ability
1000g
Release date
2023-03-10
Hong Kong Tiansheng New Material Trading Co., Ltd
Product
Darifenacin 133099-04-4
Price
US $25.99/KG
Min. Order
1KG
Purity
99%
Supply Ability
100KG
Release date
2021-12-28

133099-04-4, DarifenacinRelated Search:

tadalafi ISOXADIFEN-ETHYL Acetaminophen PHENYL VALERATE Ethanol Piracetam Acetamide Trinexapac-ethyl Ethyl acetate Ethylparaben Thioacetamide Phenyl salicylate N,N-Dimethylacetamide 2-Cyanoacetamide Solifenacin Diphenyl ether PHENYL RESIN Phenylacetic acid

  • CS-773
  • 2-(1-(2-(2,3-Dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetaMide
  • UK 88525
  • UK88525
  • UK-88525
  • 2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-dip
  • Darifenacin, >=98%
  • DARIFENACIN
  • 2-[1-[2-(2,3-Dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-di(phenyl)acetamide
  • (3S)-1-[2-(2,3-Dihydro-5-benzofuranyl)ethyl]-α,α-diphenyl-3-pyrrolidineacetamide
  • 2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-dipheny
  • 2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphe
  • 3-Pyrrolidineacetamide, 1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-α,α-diphenyl-, (3S)-
  • Darifenacin USP/EP/BP
  • (3S)-1-[2-(2,3-Dihydro-5-benzofuranyl)ethyl]-α-α-diphenyl-3-pyrrolidineacetamide Hydrobromide
  • Tolafentrine Impurity 16
  • 133099-04-4
  • Pharmaceutical material and intermeidates
  • API